SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0250 7005 OR L773:1791 7530 srt2:(2015-2019);pers:(Nilsson Anders 1958)"

Sökning: L773:0250 7005 OR L773:1791 7530 > (2015-2019) > Nilsson Anders 1958

  • Resultat 1-2 av 2
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Månsson, Christopher, Läkarexamen, 1977-, et al. (författare)
  • Percutaneous Irreversible Electroporation as First Line Treatment of Locally Advanced Pancreatic Cancer
  • 2019
  • Ingår i: Anticancer Research. - : Anticancer Research USA Inc.. - 0250-7005 .- 1791-7530. ; 39:5, s. 2509-2512
  • Tidskriftsartikel (refereegranskat)abstract
    • Background/Aim:Irreversible electroporation (IRE) has recently been used as an experimental ablation treatment following systemic chemotherapy in locally advanced pancreatic cancer (LAPC). The primary aim of this study was to evaluate survival of LAPC patients after IRE prior to chemotherapy. The secondary aim was to examine the complication rates.Patients and Methods:Twenty-four patients with LAPC were included and treated with percutaneous ultrasound-guided IRE under general anesthesia. Survival data from the National Quality Registry for Pancreatic and Periampullary Cancer for LAPC during the same period were used for comparison.Results:The median survival after diagnosis was 13.3 months in the IRE group compared to 9.9 months in the registry group (p=0.511). Six patients had a severe complication after IRE treatment.Conclusion:No obvious gain in survival was observed with IRE as the first line treatment of LAPC and IRE was associated with severe complications. This study does not support percutaneous IRE in this setting.
  •  
2.
  • Månsson, Christopher, Läkarexamen, 1977-, et al. (författare)
  • The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer
  • 2019
  • Ingår i: Anticancer Research. - : Anticancer Research USA Inc.. - 0250-7005 .- 1791-7530. ; 39:11, s. 6193-6196
  • Tidskriftsartikel (refereegranskat)abstract
    • Background/Aim:Carbohydrate antigen 19-9 (CA19-9) is a tumor marker for pancreatic cancer. Irreversible electroporation (IRE) is an experimental treatment modality for pancreatic cancer. The aim of this study was to evaluate whether percutaneous IRE lowers the CA19-9 level in pancreatic cancer and whether this correlates with improved overall survival.Patients and Methods:Seventy-one patients with locally advanced pancreatic cancer or local recurrence after resection were treated. Patients with missing data, metastatic disease and normal serum CA19-9 before IRE were excluded. This left 35 cases for analysis.Results:The median CA19-9 did not decrease in the cohort after IRE treatment (282 U/ml before versus 315 U/ml after; p=0.80). The 25th percentile of patients with the best CA19-9 response had improved overall survival compared to the 25th percentile with the worst response (mean 13.1 versus 8.1 months, respectively; p=0.01).Conclusion:IRE did not lower the level of CA19-9 in pancreatic cancer cases. However, a response in CA19-9 was correlated with improved survival.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-2 av 2
Typ av publikation
tidskriftsartikel (2)
Typ av innehåll
refereegranskat (2)
Författare/redaktör
Nilsson, Anders,... (2)Ta bort avgränsningen
Urdzik, Jozef (2)
Karlson, Britt-Marie (2)
Månsson, Christopher ... (2)
Nygren, Peter (1)
Brahmstaedt, Richard (1)
Lärosäte
Uppsala universitet (2)
Språk
Engelska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (2)
År
2019 (2)

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy